(Q58168175)

English

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months

No description defined

In more languages

Statements

scholarly article

0 references

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months (English)

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

Daria Lucia Trabattoni

object named as

Daria Trabattoni

7

0 references

Paola Marchisio

object named as

Paola Marchisio

2

0 references

Susanna Esposito

object named as

Susanna Esposito

1

0 references

Nicola Principi

9

object named as

Nicola Principi

0 references

Sonia Bianchini

4

object named as

Sonia Bianchini

0 references

6

object named as

Elena Baggi

0 references

Filippo Ansaldi

3

object named as

Filippo Ansaldi

0 references

author name string

Michela Pacei

5

0 references

Giancarlo Icardi

8

0 references

language of work or name

0 references

publication date

August 2010

0 references

0 references

28

0 references

38

0 references

6137-6144

0 references

Are we ready for universal influenza vaccination in paediatrics?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Pediatric influenza prevention and control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

The rational use of influenza vaccines in healthy children and children with underlying conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Burden of influenza in children in the community

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

The underrecognized burden of influenza in young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

The global state of influenza in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

National immunization program in Finland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Influenza vaccine dosages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Influenza-associated hospitalizations in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Influenza vaccination coverage among children with high-risk medical conditions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.041

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.07.041

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58168175&oldid=1739805928"